» Articles » PMID: 14676798

Palliative Chemotherapy or Best Supportive Care? A Prospective Study Explaining Patients' Treatment Preference and Choice

Overview
Journal Br J Cancer
Specialty Oncology
Date 2003 Dec 17
PMID 14676798
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR)=10.3, confidence interval (CI) 2.8-38.0) and a deferring style of decision-making (OR=4.9, CI 1.4-17.2) best predicted the actual treatment choice. Treatment preference (total explained variance=38.2%) was predicted, in turn, by patients' striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients' actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making.

Citing Articles

Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer.

Abdul-Aziz S, Bhattarai N, Vale L, Sagoo G, Mukhopadhyay A Gynecol Oncol Rep. 2025; 57:101680.

PMID: 39917724 PMC: 11800098. DOI: 10.1016/j.gore.2025.101680.


Understanding how shared decision-making approaches and patient aids influence patients with advanced cancer when deciding on palliative treatments and care: A realist review.

Edwards M, Holland-Hart D, Mann M, Seddon K, Buckle P, Longo M Health Expect. 2023; 26(6):2109-2126.

PMID: 37448166 PMC: 10632651. DOI: 10.1111/hex.13822.


Systemic Therapy Decision Making in Advanced Cancer: A Qualitative Analysis of Patient-Oncologist Encounters.

Wasp G, Knutzen K, Murray G, Brody-Bizar O, Liu M, Pollak K JCO Oncol Pract. 2021; 18(8):e1357-e1366.

PMID: 34855459 PMC: 9377707. DOI: 10.1200/OP.21.00377.


Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.

Younger E, Jones R, Hollander D, Soomers V, Desar I, Benson C ESMO Open. 2021; 6(5):100258.

PMID: 34509803 PMC: 8441156. DOI: 10.1016/j.esmoop.2021.100258.


Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.

Watts K, Wills C, Madi A, Palles C, Maughan T, Kaplan R Int J Cancer. 2021; 149(9):1713-1722.

PMID: 34270794 PMC: 7616640. DOI: 10.1002/ijc.33739.


References
1.
Siminoff L, Fetting J . Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med. 1991; 32(7):813-8. DOI: 10.1016/0277-9536(91)90307-x. View

2.
Sutherland H, Llewellyn-Thomas H, Lockwood G, Tritchler D, Till J . Cancer patients: their desire for information and participation in treatment decisions. J R Soc Med. 1989; 82(5):260-3. PMC: 1292127. DOI: 10.1177/014107688908200506. View

3.
Quantin X, Riviere A, Daures J, Oliver P, Khial F, Marcillac I . Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose. Am J Clin Oncol. 2000; 23(2):192-6. DOI: 10.1097/00000421-200004000-00017. View

4.
McQuellon R, Muss H, Hoffman S, Russell G, Craven B, Yellen S . Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol. 1995; 13(4):858-68. DOI: 10.1200/JCO.1995.13.4.858. View

5.
Yellen S, Cella D . Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol. 1995; 13(5):1255-64. DOI: 10.1200/JCO.1995.13.5.1255. View